Background {#Sec1}
==========

Developing countries are experiencing an upsurge in the prevalence of diabetes \[[@CR1]\], which is associated with a high risk of microvascular complications \[[@CR2]\]. For instance, the prevalence of diabetes in Cameroon has risen from 1.1 % in 1997 \[[@CR3]\] to 5.9 % in 2013 \[[@CR1]\]. It is expected that the prevalence of long-term complications of diabetes will increase accordingly due to low awareness of the disease \[[@CR1]\] and suboptimal management of those with diagnosed diabetes \[[@CR4]\]. Among the chronic microvascular diabetes complications, diabetic nephropathy may present with anemia at different stages of deterioration of the kidney function \[[@CR5]\]. Accordingly, anemia is a common feature in diabetes, with a reported prevalence of 13 % in a European population \[[@CR6]\], 23 % in an Australian population \[[@CR7]\] and up to 46.5 % in a Caribbean population \[[@CR8]\].

Chronic kidney disease (CKD) does not explain all cases of anemia in diabetes, which seems to result from an interplay between several factors that include: declining kidney function, functional erythropoietin deficiency, nutritional deficiencies, chronic inflammation, iatrogenic causes, and infectious diseases \[[@CR9]\]. As a consequence, anemia tends to occur early in diabetic patients, even in the absence of overt nephropathy, and it is more severe \[[@CR10]\]. This is largely unrecognized by both physicians and patients despite the fact that anemia negatively affects the quality of life of diabetic patients \[[@CR11]\]. Anemia is also a significant adverse prognostic factor for cardiovascular disease, and all-cause mortality in people with diabetes \[[@CR12]\]. Early identification and correction of anemia has been shown to reduce the rate of progression and even delay the onset of some microvascular complications \[[@CR13]\] as well as improve the quality of life of diabetic patients \[[@CR14]\].

Current guidelines on the management of diabetes do not recommend routine screening for anemia. Although reports on the prevalence and predictors of anemia in diabetic patients exists elsewhere, such information is very rare in sub-Saharan Africa where other potential contributory factors like infectious and genetic diseases as well as nutritional deficiencies are very frequent and likely to worsen the burden of anemia. This study aimed to assess the prevalence and investigate the role of kidney function deterioration and other predictors of anemia in a population of type 2 diabetic patients in Cameroon.

Methods {#Sec2}
=======

Study design, setting and population {#Sec3}
------------------------------------

We conducted a cross-sectional study involving all consenting patients who were receiving chronic care for type 2 diabetes at the out-patient section of the endocrine unit of the Douala General Hospital (DGH), and covered a period of activity of 6 months from 1^st^ June to 31^st^ December 2013. DGH is a tertiary care hospital located in Douala, the economic Capital of Cameroon (approximately 2.8 million inhabitants) \[[@CR15]\]. The endocrine unit of DGH is the main referral centre for endocrine diseases and diabetes in Douala. Patients with diabetes residing in Douala and surrounding regions were likely to receive care in this unit during the study period. Patients with diabetes receiving care in the unit undergo an annual evaluation that includes amongst others: a clinical evaluation, an assessment of diabetes control (HbA~1~c level), chronic complications (fundoscopy, retinography and retinal angiography where needed; dipstick proteinuria and serum creatinine), and cardiovascular risk factors assessment. The study received ethical approval from the Institutional review board of the Faculty of Health Sciences, University of Buea, and administrative clearance from the authorities of the DGH. Patients with diagnosed type 2 diabetes, irrespective of gender and aged 20 years or above, were included. All patients with a known hematologic disease, any acute condition, or those who received a blood transfusion in the preceding 4 months were excluded.

Data collection and laboratory procedures {#Sec4}
-----------------------------------------

For each consenting patient, data were collected on medical and family history, and behavioral factors (smoking, physical exercise and alcohol consumption). The weight, height, blood pressure, waist and hip circumferences were measured using standardized methods. The body mass index (BMI) was calculated as weight (in kilograms)/height × height (in meters).

The hemoglobin level was obtained from the full blood count performed by an automated analyser (Ruby Cell Dyn^®^, Abbott). The Jaffe method was used to measure serum creatinine levels using a Roche -- Hitachi Cobas C311^®^ analyser. Standard laboratory procedures were used in the measurement of HbA~1~c (immuno-turbidimetric method) and lipid profile (enzymatic method). Proteinuria was determined by dipstick.

Definitions {#Sec5}
-----------

Patients were classified as anemic according to the World Health Organization (WHO) criteria (Hb \< 12 g/dl for females and \<13 g/dl for males) \[[@CR16]\]. A second definition of anemia was also used based on the suggested threshold of Hb \< 11 g⁄dl (for both sexes) for the initiation of treatment with erythropoietin for anemia in chronic kidney disease \[[@CR17]\]. Based on mean corpuscular volume (MCV), anemia was classified as microcytic (MCV \< 80 fl), normocytic (MCV between 80 and 100 fl) or macrocytic (MCV \> 100 fl). Mean corpuscular hemoglobin concentration (MCHC) was used to characterize anemia as hypochromic (MCHC \<32 g/dl), or normochromic (MCHC ≥32 g/dl). Estimated glomerular filtration rate (eGFR) (ml/min/1.73 m^2^) was calculated using the abbreviated Modification of Diet in Renal Disease (MDRD) Study Group formula as eGFR =186 × \[serum creatinine (mg/l)\]^−1.154^ × \[age (years)\]^−0.203^ × 0.192 × (0.742 for female) \[[@CR18]\]. Based on eGFR (ml/min/1.73 m^2^), patients were further classified into the five stages of chronic kidney disease (CKD) as follows: stage 1 (eGFR ≥90); stage 2 (eGFR between 60 and 89); stage 3 (eGFR between 30 and 59); stage 4 (eGFR between 15 and 29) and stage 5 (eGFR \<15) \[[@CR17], [@CR18]\].

Statistical analysis {#Sec6}
--------------------

Data were analyzed using SAS/STAT v.9.1 for Windows^®^ (SAS Institute Inc., Cary, NC, USA). We used the chi squared test for comparison of categorical variables, and the Student *t*-test or Kruskal-Wallis test for continuous variables. Results are presented as count (percentages), mean and standard deviation (SD) or median and 25^th^-75^th^percentiles as appropriate. Pearson correlation was used to assess univariate associations between continuous variables. Multivariable logistic regressions were used to identify determinants of anemia; odd ratio (OR) with 95 % confidence intervals (CI) are presented. A *p*-value \<0.05 was used to characterize statistically significant results.

Sample size estimation {#Sec7}
----------------------

The sample size was estimated assuming a prevalence of anemia of 40 % based on a previous study in people with diabetes in Nigeria \[[@CR19]\], a precision of 5 % and a z value of 1.96. Based on these assumptions a minimum of 370 participants was required.

Results {#Sec8}
=======

General characteristics of participants {#Sec9}
---------------------------------------

We included 636 type 2 diabetic patients (53.1 % males) aged 20 to 86 years (mean age 56.5 ± 10.6 years), with a median known duration of diabetes of 4 years (25^th^--75^th^ percentiles, 1--9). Compared with males, females were more likely to be overweight or obese (76.1 % vs. 70.1 %, *p* = 0.042), had poorer diabetes control based on mean HbA1c (8.5 % vs. 8.1 %, *p* = 0.046) and were less likely to be current smokers (4.4 % vs. 15.9 %, *p* \< 0.001) (Table [1](#Tab1){ref-type="table"}). Other baseline characteristics of the participants are summarized in Table [1](#Tab1){ref-type="table"}.Table 1General characteristics of participantsVariablesWomen (*n* = 298)Men (*n* = 338)*p*-valueTotal (*n* = 636)Mean age (years)57.6 ± 11.555.6 ± 9.70.19056.5 ± 10.6Smoking13 (4.4)53 (15.9)\<0.00166 (10.4)Body mass index (kg/m^2^)30.5 ± 6.628.2 ± 5.1\<0.00129.3 ± 14.7Overweight or obese (BMI ≥ 25 kg/m^2^)228 (76.5)237 (70.1)0.042465 (73.3)Obese (BMI ≥ 30 kg/m^2^)124 (44.6)100 (32.1)0.009224 (38.4)Waist circumference (cm)97.3 ± 12.498.7 ± 12.90.16798.0 ± 12.7Hip circumference (cm)108.4 ± 13.3102.8 ± 10.7\<0.001105.4 ± 12.3Abdominal obesity^a^252 (84.6)198 (58.6)\<0.001450 (70.8)Systolic blood pressure (mmHg)136.2 ± 21.1137.7 ± 22.40.339137.0 ± 21.8Diastolic blood pressure (mmHg)82.4 ± 1282.1 ± 12.60.76482.3 ± 12.3Hypertension188 (63.3)206 (61.0)0.542394 (62.2)Any BP-lowering medication168 (56.4)184 (54.4)0.576352 (55.3)ACEI/ARB145 (48.7)163 (48.2)0.575308 (48.4)Diuretics104 (34.9)114 (33.7)0.654218 (34.3)Calcium channel blockers72 (24.2)68 (20.1)0.129140 (22.0)Beta blockers7 (2.3)6 (1.8)0.41013 (2.0)Use of metformin244 (81.9)268 (79.3)0.696512 (80.5)Use of sulfonylureas172 (57.7)192 (56.8)0.585364 (57.2)Use of Acarbose6 (2.0)8 (2.4)0.33514 (2.2)Use of Insulin31 (10.4)37 (10.9)0.38368 (10.7)HbA1c (%)8.5 ± 2.68.1 ± 2.50.0468.6 ± 2.5Fasting capillary glucose (mg/dl)150 ± 60140 ± 600.646150 ± 60Any diabetic retinopathy52 (22.4)83 (30.4)0.080135 (26.7)Any diabetic nephropathy83 (31.6)128 (40.9)0.020211 (36.6)Any diabetic neuropathy141 (51.1)165 (52.4)0.821306 (51.7)Serum Creatinine (mg/dl)0.93 ± 0.361.22 ± 0.58\<0.0011.08 ± 0.47eGFR (ml/min/1.73 m^2^)86.2 ± 30.486.2 ± 32.0≥0.99986.2 ± 31.7Data are presented as number (%) or mean ± standard deviation;*Abbreviations*: *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *BMI* body mass index, *BP* blood pressure, *eGFR* estimated glomerular filtration rate, *HbA1c* glycated hemoglobin^a^Abdominal obesity: waist circumference \>80 cm in females or \>94 cm in males

Prevalence and distribution of anemia {#Sec10}
-------------------------------------

The mean hemoglobin (Hb) levels were 13.2 ± 2.0 g/dl in males and 12.3 ± 1.5 g/dl in females (*p* \< 0.001). According to the WHO criteria, 263 patients (41.4 %) had anemia. The prevalence was 42.6 % in females (*n* = 127) and 40.2 % in males (*n* = 136). Using the threshold recommended for intervention (Hb \< 11 g/dl for both sexes), 91 patients (14.3 %), including 48 females (prevalence 16.1 %) and 43 males (prevalence 12.7 %), had anemia.

The average mean corpuscular volume (MCV) in the total population was 86.3 ± 7.7 fl. The difference in the distribution of mean corpuscular volume categories between patients with anemia and those without anemia was significant (*p* \< 0.001), with anemic patients having more microcytosis and macrocytosis than non-anemic patients (Table [2](#Tab2){ref-type="table"}). The average MCHC was 32.4 ± 2.7 in the total population. Low MCHC was more common in anemic than non-anemic participants, 103 (47.3 %) and 100 (38.3 %) respectively (*p* = 0.05) (Table [2](#Tab2){ref-type="table"}).Table 2Comparison of red cell parameters categories between anemic and non-anemic patientsVariableAnemia^a^ (*n* = 263)No anemia (*n* = 373)Normocytosis\* (MCV 80--100 fl)73.382.1Microcytosis\* (MCV \< 80 fl)21.415.1Macrocytosis\* (MCV \> 100 fl)5.42.9Normochromia (MCHC 32--36 g/dl)52.861.7Hypochromia (MCHC \< 32 g/dl)47.338.3^a^Anemia defined as hemoglobin concentration \<12 g/dl for females and \<13 g/dl for males\**p* value \< 0.05

Kidney function and anemia {#Sec11}
--------------------------

Proteinuria was positive in 68.4 % (*n* = 180) of patients with anemia as compared with 57.6 % (*n* = 215) of patients without anemia (*p* = 0.001). The mean eGFR of the 584 patients (91.2 %) with eGFR data was 86.2 ± 31.7 ml/min/1.73 m^2^. Patients with anemia had lower mean eGFR than patients without anemia (72.9 ± 35.7 vs. 89.6 ± 29.5 ml/min/1.73 m^2^, *p* \< 0.001), and the Pearson correlation coefficient between the eGFR and the hemoglobin level was 0.29 (*p* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Correlation between the hemoglobin level and the estimated glomerular filtration rate. Squares represent individual hemoglobin levels of participants. The red line is the linear regression line

Two hundred and fifty (42.8 %) participants had normal kidney function (eGFR ≥90 ml/min/1.73 m^2^) among whom 80 (31.9 %) were anemic compared with 160 (48.0 %) in patients with any CKD (*p* \< 0.001). As kidney function deteriorated, the prevalence of anemia increased (Fig. [2](#Fig2){ref-type="fig"}). Compared with patients with normal eGFR, patients with CKD (eGFR \< 90 ml/min/1.73 m^2^) of any degree were about two times more likely to have anemia at levels where treatment was required.Fig. 2Prevalence of anemia by estimated glomerular filtration rate categories. Red bars represent anemia based on the World Health Organization definition; blue bars represent anemia based on threshold for intervention. Numbers above the bars denote the prevalence of anemia in each category of estimated glomerular filtration rate

Among the 108 (18.5 %) patients with chronic renal failure (CRF) (eGFR \< 60 ml/min/1.73 m^2^), 40 (37.0 %) had anemia at levels requiring therapeutic intervention, about four times higher than the 9.7 % in patients without CRF (*p* \< 0.001).

Other determinants of hemoglobin levels and anemia {#Sec12}
--------------------------------------------------

Correlation coefficients between continuous variables and hemoglobin levels are shown in Table [3](#Tab3){ref-type="table"}. Age, known duration of diabetes, systolic and diastolic blood pressure levels and serum creatinine were inversely correlated with hemoglobin levels, while waist and hip circumference, fasting glucose, HbA1c, and triglycerides were positively correlated with hemoglobin levels.Table 3Correlation between hemoglobin level and other variablesVariable*r* (Pearson)*p*Age−0.100.017Duration of Diabetes−0.18\<0.001Systolic BP−0.110.005Diastolic BP−0.100.011Waist Circumference0.15\<0.001Hip Circumference0.100.040eGFR0.29\<0.001Fasting Blood Sugar0.16\<0.001HbA1c0.120.009Triglyceride0.15\<0.001Serum Creatinine−0.07\<0.001*Abbreviations*: *BP* blood pressure, *eGFR* estimated glomerular filtration rate

In multivariable logistic regressions, only eGFR \[OR: 1.01 (95 % CI 1.00--1.02) per unit higher eGFR; *p* = 0.001\] and the presence of diabetic retinopathy \[OR: 2.32 (95 % CI 1.39--3.85); *p* = 0.023\] were independent determinants of anemia.

Discussion {#Sec13}
==========

In this study, we found that two in five patients with type 2 diabetes had anemia. This high prevalence was mainly driven by diabetes complications, as the presence of retinopathy and declining kidney function were the independent determinants of anemia. We also observed that one third of diabetic patients with normal kidney function had anemia.

Anemia is a common finding in patients with diabetes and has a negative impact on the patient's sense of wellbeing; it also impairs the ability to work, reduces the quality of life \[[@CR20]\] and worsens cardiovascular health \[[@CR12]\]. The prevalence of anemia in our study (41.4 %) was relatively higher than that reported in the general adult population in Cameroon (34 %) \[[@CR21]\]. The prevalence of anemia in diabetic patients reported elsewhere is comparable to, or lower than our finding, depending on the level of development of the country, the geographical altitude and the age of the study population: 46.5 % in Caribbean population \[[@CR8]\], 17 % in Ethiopia \[[@CR22]\] and 12 \[[@CR6]\] to 23 % \[[@CR7]\] in Caucasians. The higher altitude in Ethiopia and their younger study population may account for the lower prevalence, whereas the high prevalence of infectious causes and nutritional deficiencies, asymptomatic inherited hemoglobinopathies, and suboptimal glycemic control in our population could explain the higher prevalence in the present study compared with Caucasians \[[@CR23]\]. The high prevalence of microcytosis in our study suggests the importance of non-renal causes of anemia in diabetes patients in this setting. This may have implications on the management options. However, further research is needed to fully investigate the spectrum of the etiology of anemia in African populations with diabetes.

In Cameroon, the prevalence CKD is about 13.2 % in the adult population, with the rate being higher amongst rural dwellers, and risk factors profile being similar to those in Caucasian populations \[[@CR24]\]. In accordance with previous studies \[[@CR6]--[@CR8], [@CR10], [@CR22], [@CR25]\] our findings illustrate the negative role of renal function decline in the development and progression of anemia in patients with diabetes. However, the absence of overt kidney disease was not protective against anemia, as 31.9 % of patients with normal eGFR had anemia; this proportion is high when compared with findings in other populations−13 % in China \[[@CR25]\]. This observation emphasizes the role of other aforementioned contributors to anemia in diabetic patients in Cameroon.

Our finding that retinopathy was a significant determinant of anemia is in line with previous reports in India \[[@CR26]\]. This is probably because diabetes retinopathy is usually associated with diabetes nephropathy. However, anemia may in turn play a pervasive role on the microvascular complications \[[@CR27]\]. Although HbA1c was not an independent determinant of anemia, patients with normal hemoglobin levels had significantly higher level of HbA1c than anemic patients, as observed by other authors \[[@CR25]\]. This raises caution in interpreting HbA1c levels in diabetic patients in Africa, as anemia has also been shown to spuriously lower HbA1c \[[@CR28]\].

We acknowledge the following potential limitations of our study. Since it was conducted in a tertiary care hospital, results may overestimate the actual burden of anemia in diabetic patients in primary healthcare. Also this study was not designed to identify the causes of anemia in diabetic patients, indicating the need for further research in this domain. The reticulocyte count and the role of chronic inflammation on prevalent anemia was not assessed, and the presence of hemoglobinopathies was not investigated. However, we had a relatively large sample size of routinely monitored type 2 diabetic patients and we used robust statistical tests to identify the determinants.

Conclusions {#Sec14}
===========

In conclusion, the prevalence of anemia in the type 2 diabetic population in Cameroon is high, including in patients with normal kidney function. However, declining kidney function appears as the main determinant. Our findings suggest that patients with diabetes should be routinely screened for anemia, and have other non-renal causes checked. Further, the findings raise issues regarding the added economic burden to diabetic patients attributable to anemia, and the cautious interpretation of the HbA1c level in sub-Saharan Africans.
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